DEF: Viridian Therapeutics Seeks Stockholder Approval for Amended Equity Incentive Plan and New Employee Stock Purchase Plan

Viridian Therapeutics is asking stockholders to approve an amended equity incentive plan with an increased share pool and a new employee stock purchase plan at the upcoming annual meeting.

Summary

• Viridian Therapeutics is soliciting proxies for its 2025 Annual Meeting of Stockholders to be held on June 20, 2025.
• The meeting will be conducted virtually.
• Key proposals include the election of three Class I directors, ratification of KPMG LLP as the independent auditor, an advisory vote on executive compensation, approval of an amendment to the 2016 Equity Incentive Plan to increase the number of shares available by 8,000,000, and approval of the 2025 Employee Stock Purchase Plan (ESPP).
• The Board recommends voting FOR all director nominees and FOR all proposals.
• The record date for determining stockholders eligible to vote is April 22, 2025.
• The proxy materials are available online at www.proxyvote.com.
• The company is seeking approval for an additional 8,000,000 shares under the Amended 2016 Equity Incentive Plan.
• If approved, the aggregate number of shares of stock available for issuance under the Amended 2016 Plan will be 18,297,643 shares of common stock plus any shares of common stock subject to outstanding awards under the 2020 Plan and 2008 Plan as of March 31, 2025 that on or after such date are forfeited, terminated, expire or otherwise lapse without being exercised (to the extent applicable), or are settled in cash.
• The company is also seeking approval for the Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan (the '2025 ESPP') with 2,000,000 shares of common stock available for issuance.
• The company estimates that the current equity pool under the Existing 2016 Plan will be insufficient to support its retention and hiring objectives and that it will run out of equity to grant from its pool as soon as March 2026.

Sentiment

Score: 7

Explanation: The document is largely procedural, outlining proposals for stockholder voting. The tone is professional and focused on corporate governance, with a slightly positive outlook regarding the company's future growth and talent acquisition.

Positives

• Approval of the share increase is expected to meet the company's anticipated needs for approximately two years based on historical equity grant practices and planned headcount.
• The company believes that the approval of this proposal is instrumental to its continued success, particularly as it prepares for a potential commercial launch of veligrotug, if approved, advance VRDN-003 through pivotal trials and topline data readouts, and advance its FcRn inhibitor pipeline.

Negatives

• If stockholders do not approve the Share Increase, the company anticipates running out of equity to grant from its pool as soon as March 2026.
• The company's three-year average burn rate through December 31, 2024, remained elevated at approximately 12.7% (F1) or 9.3% (F2).

Risks

• Failure to approve the share increase could negatively impact the company's ability to attract and retain talent.
• The company's three-year average burn rate is atypically high due to extraordinary circumstances in 2023, which may raise concerns about dilution.

Future Outlook

The company anticipates its headcount doubling over the next two years and believes that the ability to grant sufficient equity to its employees is key to its ability to attract and retain the outstanding and highly skilled individuals needed.

Industry Context

The document highlights the competitive landscape for biotech talent, particularly in Massachusetts, emphasizing the importance of equity awards in attracting and retaining qualified personnel.

Comparison to Industry Standards

• The company uses a comparative framework to identify specific peer companies and data sources to assess and develop its executive pay philosophy and compensation positioning.
• The company's compensation peer group for 2024 included Aerovate Therapeutics, Akero Therapeutics, AnaptysBio, Arcus Biosciences, Arcutis Biotherapeutics, Celldex Therapeutics, Crinetics Pharmaceuticals, Day One Biopharmaceuticals, Immunovant, KalVista Pharmaceuticals, Keros Therapeutics, Kiniksa Pharmaceuticals, Kura Oncology, Mersana Therapeutics, Morphic Holding, Pliant Therapeutics, Prothena, Replimune Group, Sutro Biopharma, Syndax Pharmaceuticals, Ventyx Biosciences, and Viking Therapeutics.
• In September 2024, the Compensation Committee approved changes to the peer group for purposes of assessing executive compensation for 2025, removing Aerovate Therapeutics, Arcutis Biotherapeutics, Crinetics Pharmaceuticals, Immunovant, Mersana Therapeutics, Ventyx Biosciences, and Viking Therapeutics and adding Cogent Biosciences, Erasca, Ocugen, Praxis Precision Medicines, and Vera Therapeutics.

Related Party Transactions

• The Paragon Agreements may be considered related party transactions because Fairmount beneficially owns more than 5% of our capital stock, has two seats on our Board and is also a 5% or greater stockholder of Paragon, which is a joint venture between Fairmount and FairJourney Biologics, and has appointed the sole director on Paragons board of directors and has the contractual right to approve the appointment of any executive officers.
• The Zenas BioPharma Agreements may be considered related party transactions because Fairmount beneficially owns more than 5% of our capital stock, has two seats on our Board and is also a 5% or greater stockholder of Zenas BioPharma and has a seat on Zenas BioPharmas board of directors.

Stakeholder Impact

• Approval of the proposals is intended to benefit stockholders by aligning employee incentives with company performance and supporting long-term growth.
• Employees may benefit from the opportunity to purchase company stock through the ESPP and receive equity awards under the incentive plan.
• The company's ability to attract and retain talent is crucial for its success and ultimately benefits all stakeholders.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on June 20, 2025.
• The company will implement the approved proposals, including the amended equity incentive plan and the new employee stock purchase plan.

Key Dates

Keywords

proxy statement, annual meeting, equity incentive plan, employee stock purchase plan, director election, executive compensation, KPMG, stockholders, Viridian Therapeutics